Revisiting the Design of Phase III Clinical Trials of Antimalarial Drugs for Uncomplicated Plasmodium falciparum Malaria

Steffen Borrmann and colleagues discuss appropriate endpoints and their measurement during phase III trials of new antimalarial drugs.

[1]  A. Hubbard,et al.  Efficacy studies of malaria treatments in Africa: efficient estimation with missing indicators of failure , 2008, Statistical methods in medical research.

[2]  K. Barnes,et al.  Antimalarial dosing regimens and drug resistance. , 2008, Trends in parasitology.

[3]  P. Kremsner,et al.  Effects of Plasmodium falciparum Parasite Population Size and Patient Age on Early and Late Parasitological Outcomes of Antimalarial Treatment in Children , 2008, Antimicrobial Agents and Chemotherapy.

[4]  N. White.  How antimalarial drug resistance affects post-treatment prophylaxis , 2008, Malaria Journal.

[5]  M. Gatton,et al.  Can estimates of antimalarial efficacy from field studies be improved? , 2008, Trends in parasitology.

[6]  F. Checchi,et al.  Risk associated with asymptomatic parasitaemia occurring post‐antimalarial treatment , 2008, Tropical medicine & international health : TM & IH.

[7]  A. Djimde,et al.  Monitoring and deterring drug-resistant malaria in the era of combination therapy. , 2007, The American journal of tropical medicine and hygiene.

[8]  Abdullah S Ali,et al.  Impact of Artemisinin-Based Combination Therapy and Insecticide-Treated Nets on Malaria Burden in Zanzibar , 2007, PLoS medicine.

[9]  R. Price,et al.  Clinical and Pharmacological Determinants of the Therapeutic Response to Dihydroartemisinin-Piperaquine for Drug-Resistant Malaria , 2007, Antimicrobial Agents and Chemotherapy.

[10]  R. Price,et al.  World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs , 2007, Malaria Journal.

[11]  S. Hoffman,et al.  Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. , 2007, The Journal of infectious diseases.

[12]  A. Hubbard,et al.  Impact of Transmission Intensity on the Accuracy of Genotyping To Distinguish Recrudescence from New Infection in Antimalarial Clinical Trials , 2007, Antimicrobial Agents and Chemotherapy.

[13]  R. Snow,et al.  The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya , 2007, Malaria Journal.

[14]  P. Rosenthal,et al.  Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Malaria: A Randomized Trial , 2007, PLoS clinical trials.

[15]  J. Carlton,et al.  Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. , 2007, The Journal of infectious diseases.

[16]  R. Price,et al.  Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison , 2007, The Lancet.

[17]  P. Rosenthal,et al.  Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial , 2007, The Lancet.

[18]  K. Stepniewska,et al.  Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria , 2006, Malaria Journal.

[19]  P. Rosenthal,et al.  The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995–2005 , 2006, Malaria Journal.

[20]  Solomon Nwaka,et al.  Innovative lead discovery strategies for tropical diseases , 2006, Nature Reviews Drug Discovery.

[21]  Hiroshi Nishiyama,et al.  Points to consider on switching between superiority and non-inferiority. , 2006, British journal of clinical pharmacology.

[22]  F. Checchi,et al.  Methodological Issues in the Assessment of Antimalarial Drug Treatment: Analysis of 13 Studies in Eight African Countries from 2001 to 2004 , 2006, Antimicrobial Agents and Chemotherapy.

[23]  I. Bathurst,et al.  Medicines for Malaria Venture: sustaining antimalarial drug development. , 2006, Trends in parasitology.

[24]  R. Price,et al.  Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  P. Rosenthal,et al.  Complexity of Plasmodium falciparum infections and antimalarial drug efficacy at 7 sites in Uganda. , 2006, The Journal of infectious diseases.

[26]  N. Day,et al.  Pitfalls in Estimating Piperaquine Elimination , 2005, Antimicrobial Agents and Chemotherapy.

[27]  T. Mutabingwa,et al.  Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy! , 2005, Acta tropica.

[28]  P. Rosenthal,et al.  Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. , 2005, The American journal of tropical medicine and hygiene.

[29]  F. Checchi,et al.  Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial , 2005, The Lancet.

[30]  S. Hay,et al.  The global distribution of clinical episodes of Plasmodium falciparum malaria , 2005, Nature.

[31]  Grant Dorsey,et al.  Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial , 2004, The Lancet.

[32]  R. Price,et al.  In Vivo Assessment of Drug Efficacy against Plasmodium falciparum Malaria: Duration of Follow-Up , 2004, Antimicrobial Agents and Chemotherapy.

[33]  Kevin Carroll,et al.  Design and analysis of non‐inferiority mortality trials in oncology , 2004, Statistics in medicine.

[34]  H. Myint,et al.  A systematic overview of published antimalarial drug trials. , 2004, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[35]  O. Traoré,et al.  Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. , 2003, The American journal of tropical medicine and hygiene.

[36]  R. Snow,et al.  Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa. , 2003, Trends in parasitology.

[37]  Mark Rothmann,et al.  Design and analysis of non‐inferiority mortality trials in oncology , 2002, Statistics in medicine.

[38]  Kenneth F Schulz,et al.  Generation of allocation sequences in randomised trials: chance, not choice , 2002, The Lancet.

[39]  R. Snow,et al.  The past, present and future of childhood malaria mortality in Africa. , 2001, Trends in parasitology.

[40]  P. Rosenthal,et al.  Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial , 2001, The Lancet.

[41]  J. M. Rubio,et al.  Genotyping of Plasmodium falciparum infections by PCR: a comparative multicentre study. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[42]  N. White,et al.  Assessment of the pharmacodynamic properties of antimalarial drugs in vivo , 1997, Antimicrobial agents and chemotherapy.

[43]  J A Lewis,et al.  Trials to assess equivalence: the importance of rigorous methods , 1996, BMJ.

[44]  R. Snow,et al.  Indicators of life-threatening malaria in African children. , 1995, The New England journal of medicine.

[45]  T. Smith,et al.  Attributable fraction estimates and case definitions for malaria in endemic areas. , 1994, Statistics in medicine.

[46]  Organización Mundial de la Salud.  Guidelines for the treatment of malaria , 2010 .

[47]  R. Price,et al.  Intrahost selection of Plasmodium falciparum pfmdr1 alleles after antimalarial treatment on the northwestern border of Thailand. , 2007, The Journal of infectious diseases.

[48]  Douglas G Altman,et al.  Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. , 2006, JAMA.

[49]  R. Snow,et al.  Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria , 2003 .

[50]  R. Snow,et al.  The consequences of reducing transmission of Plasmodium falciparum in Africa. , 2002, Advances in parasitology.